Reviewing Cyclacel Pharmaceuticals Inc. (CYCC)’s and Zafgen Inc. (NASDAQ:ZFGN)’s results

Both Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) and Zafgen Inc. (NASDAQ:ZFGN) are Biotechnology companies, competing one another. We will contrast their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cyclacel Pharmaceuticals Inc. N/A 0.00 7.51M -0.63 0.00
Zafgen Inc. N/A 0.00 59.88M -2.04 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of Cyclacel Pharmaceuticals Inc. and Zafgen Inc.


Table 2 has Cyclacel Pharmaceuticals Inc. and Zafgen Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Cyclacel Pharmaceuticals Inc. 0.00% -38.8% -31.9%
Zafgen Inc. 0.00% -80.1% -58.4%

Risk and Volatility

Cyclacel Pharmaceuticals Inc.’s current beta is 3.24 and it happens to be 224.00% more volatile than S&P 500. Competitively, Zafgen Inc. is 135.00% less volatile than S&P 500, because of the -0.35 beta.


The Current Ratio and Quick Ratio of Cyclacel Pharmaceuticals Inc. are 5.2 and 5.2 respectively. Its competitor Zafgen Inc.’s Current Ratio is 11.8 and its Quick Ratio is 11.8. Zafgen Inc. can pay off short and long-term obligations better than Cyclacel Pharmaceuticals Inc.

Analyst Recommendations

The Ratings and Recommendations for Cyclacel Pharmaceuticals Inc. and Zafgen Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Cyclacel Pharmaceuticals Inc. 0 0 1 3.00
Zafgen Inc. 0 0 1 3.00

Cyclacel Pharmaceuticals Inc. has a 887.53% upside potential and a consensus price target of $8.

Institutional & Insider Ownership

Cyclacel Pharmaceuticals Inc. and Zafgen Inc. has shares held by institutional investors as follows: 5.6% and 91.5%. Insiders held 18.62% of Cyclacel Pharmaceuticals Inc. shares. Insiders Competitively, held 0.3% of Zafgen Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cyclacel Pharmaceuticals Inc. -5.08% -32.8% -44% -39.57% -54.1% -51.72%
Zafgen Inc. 1.79% -49.46% -46.73% -21.8% 33.25% 11.04%

For the past year Cyclacel Pharmaceuticals Inc. has -51.72% weaker performance while Zafgen Inc. has 11.04% stronger performance.


Cyclacel Pharmaceuticals Inc. beats on 4 of the 6 factors Zafgen Inc.

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The companyÂ’s oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes. Its oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase (CDK) inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors. In addition, the companyÂ’s oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from metabolic diseases comprising type 2 diabetes and obesity. The companyÂ’s lead product candidate is ZGN-1061, a fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is in Phase 1 clinical trial and profiled for its utility in the treatment of metabolic diseases. Zafgen, Inc. was founded in 2005 and is based in Boston, Massachusetts.